2026-06-14T03:52:30Zhttps://repisalud.isciii.es/rest/oai/request
oai:repisalud.isciii.es:20.500.12105/202992024-11-28T18:50:48Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16963col_20.500.12105_16967
Repisalud author Lazaro, M author Gallardo, E author Domenech, M author Pinto, A author Gonzalez Del Alba, Aranzazu author Puente, J author Fernandez, O author Font, Albert author Lainez, N author Vazquez, S 2024-07-09T09:14:23Z 2024-07-09T09:14:23Z 2016-12 Lazaro M, Gallardo E, Domenech M, Pinto A, Gonzalez Del Alba A, Puente J, et al. SEOM Clinical Guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2016). Clin Transl Oncol. 2016 Dec;18(12):1197-205. Epub 2016 Nov 29. 10.1007/s12094-016-1584-z 1699-3055 1699-048X Clinical & Translational Oncology http://hdl.handle.net/20.500.13003/10075 27900539 L613533235 2-s2.0-85002180322 http://hdl.handle.net/20.500.12105/20299 389970300006 The goal of this article is to provide recommendations for the diagnosis and treatment of muscle-invasive and metastatic bladder cancer. The diagnosis of muscle-invasive bladder cancer is made by pathologic evaluation after transurethral resection. Recently, a molecular classification has been proposed. Staging of muscle-invasive bladder cancer must be done by computed tomography scans of the chest, abdomen and pelvis and classified on the basis of UICC system. Radical cystectomy and lymph node dissection are the treatment of choice. In muscle-invasive bladder cancer, neoadjuvant chemotherapy should be recommended in patients with good performance status and no renal function impairment. Although there is insufficient evidence for use of adjuvant chemotherapy, its use must be considered when neoadjuvant therapy had not been administered in high-risk patients. Multimodality bladder-preserving treatment in localized disease is an alternative in selected and compliant patients for whom cystectomy is not considered for clinical or personal reasons. In metastatic disease, the first-line treatment for patients must be based on cisplatin-containing combination. Vinflunine is the only drug approved for use in second line in Europe. Recently, immunotherapy treatment has demonstrated activity in this setting. eng Bladder cancer Cystectomy Chemotherapy Clinical guidelines SEOM Clinical Guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2016) research article